Mosaic Biosciences provides an integrated biologics discovery platform that combines antibody generation, protein engineering, functional screening, and translational pharmacology within a single organization. By leveraging proprietary naïve libraries, NGS‑driven affinity maturation, and early developability analytics, they deliver rank‑ordered therapeutic candidates—antibodies, multispecifics, cytokines, and engineered scaffolds—for biotech and pharma partners, accelerating progression from target identification to preclinical candidate selection.
Funding
$11.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biologic drug discovery often requires coordinating multiple specialized services—antibody generation, protein engineering, functional screening, and pharmacology—across separate vendors, leading to fragmented workflows, longer timelines, and higher risk of late-stage failure.
Solution
Mosaic Biosciences acts as an integrated biologics discovery partner, combining antibody discovery, protein design, cell‑based functional assays, analytical developability assessment, and translational pharmacology within a single organization. The company leverages proprietary naïve Fab and VHH libraries, NGS‑driven repertoire analysis, and yeast‑display library engineering to generate and optimize binders with early developability screening. By embedding scientists directly into partner teams, Mosaic aligns on goals and success criteria from target identification through candidate nomination, delivering rank‑ordered leads with binding kinetics, epitope mapping, stability data, and clear decision paths. The end‑to‑end platform supports diverse modalities—including antibodies, multispecifics, cytokines, and engineered scaffolds—across oncology, immunology, ophthalmology, and rare diseases, enabling faster, more confident progression to IND‑enabling studies.
Target Audience
Primary customers are biotechnology and pharmaceutical companies seeking a single partner to accelerate antibody or protein therapeutic discovery, from early target validation through preclinical candidate selection.
Features
- Integrated in vivo immunization and in vitro display workflows (phage and yeast) to discover functional binders across Fab and VHH formats
- Proprietary high‑diversity naïve libraries with common‑light‑chain strategies for bispecific development, eliminating the need for humanization
- NGS‑driven repertoire mining and CDR shuffling for rapid affinity maturation, specificity refinement, and liability reduction
- Early developability analytics (aggregation, PTM risk, expression) combined with cell‑based functional assays to de‑risk candidates before nomination
- Computational design and humanization pipelines that improve manufacturability and reduce immunogenicity risk
- Platform‑agnostic expression and purification across bacterial, yeast, insect, and mammalian systems, including site‑specific bioconjugation and glycoengineering
- Integrated translational pharmacology studies to evaluate efficacy, mechanism of action, and in vivo activity of candidate biologics
- Flexible collaboration models allowing engagement of individual services or a full end‑to‑end discovery program